NEW YORK (GenomeWeb) – Calling current market conditions unattractive, cardiovascular disease molecular diagnostics firm CardioDx is withdrawing its planned initial public offering.

The company filed a request with the US Securities and Exchange Commission on Tuesday to withdraw its IPO, saying, "The terms currently obtainable in the public marketplace are not sufficiently attractive to the [company] to warrant proceeding with the public offering."